XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Note 1 - Summary of Operations and Significant Accounting Policies (Details Textual)
$ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Research and Development Expense, Gross | $ $ 4,905 $ 5,142
Customer Funded Research and Development Expense Included in Cost of Goods Sold | $ 397 405
Research and Development, Revenue | $ $ 397 $ 405
Weighted Average Number Diluted Shares Outstanding Adjustment, Total 465,004  
Number of Operating Segments 2  
Employee Stock Option [Member]    
Incremental Common Shares Attributable to Share-based Payment Arrangements, Total 1,127,837 1,035,711
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 448,250 824,500
Restricted Stock [Member]    
Incremental Common Shares Attributable to Share-based Payment Arrangements, Total 17,500 330,676
Restricted Stock Units (RSUs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance   0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]    
Number of Major Customers 1 1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Large Defense Primary Contractor, 1 [Member]    
Concentration Risk, Percentage 16.00% 18.00%